CURRICULUM VITAE
ANTONIO CURTI
Born in Bologna (Italy) 14.05.1972
EDUCATION AND TRAINING
1997
MD degree at the University of Bologna, School of Medicine
1998
Board Certification by “Ordine provinciali dei Medici e Chirurghi di Bologna” ( #209002 )
1998-2000
Fellow in Experimental and Clinical Hematology at the University of Bologna, School of Medicine
2002
PhD in Clinical and Experimental Hematology
1998
Visiting Investigator at the Department of Dermatology, Immunotherapy Unit, Erlangen (Germany)
2000-2002 Research Fellow at the Department of Experimental Oncology, Gene Therapy and Immunotherapy Unit,
Istituto Nazionale dei Tumori, Milan, Italy
2003
Visiting Investigator at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University,
Division of Immunology and Hematopoiesis, Baltimore (USA)
RESEARCH ACTIVITY
From 1997 Research Fellow at the Institute of Hematology “L.&A. Seràgnoli”, Cell Therapy Unit
From 2008 Responsible for Immunology and Immunotherapy Research Programme at “Seragnoli” Institute.
In particular:
o basic immunology projects of tumor escape mechanisms in leukemia: the role of indoleamine 2,3dioxygenase
o DC-based vaccine trial in multiple myeloma patients
o Adoptive immunotherapy with alloreactive NK cells in acute myeloid leukemia patients
AFFILIATION
From 2006 – Attending Physician at the Institute of Hematology “L.&A. Seràgnoli”, University of Bologna, Italy.
Author of 50 papers:16 (first and corresponding author) e 3 (last author)
Total citations: 2478
Total H-index: 24
Total Impact factor: 266.13 (mean: 5.3)
PUBLICATIONS
1.
Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R,
Evangelisti C, Laury-Kleintop L, Romero P,
Prendergast GC, Curti A* and Lemoli
RM*.*EQUALLY CONTRIBUTED. The SOCS3-independent expression of IDO2
supports the homeostatic generation of T regulatory cells by human dendritic cells. J
Immunol. 2014 Feb 1;192(3):1231-40 (5,5)
2. Arpinati M, Curti A. Immunotherapy in acute myeloid leukemia. Immunotherapy. 2014
Jan;6(1):95-106. (2,3)
3. Sartor C, Papayannidis C, Chiara Abbenante M, Curti A, Polverelli N, Ottaviani E,
Iacobucci I, Guadagnuolo V, Martinelli G. A case report of acute myeloid leukemia and
neurofibromatosis 1. Hematol Rep. 2013 Jul 3;5(2):28-9.
4. Catani L, Sollazzo D, Trabanelli S, Curti A, Evangelisti C, Polverelli N, Palandri F,
Baccarani M, Vianelli N, Lemoli RM. Decreased expression of indoleamine 2,3dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in
immune thrombocytopenia. Ann Hematol. 2013 Jan;92(1):67-78. (2,8)
5. Trabanelli S, Ocadlíková D, Gulinelli S, Curti A, Salvestrini V, de Paula Vieira R, Idzko M,
Di Virgilio F, Ferrari D, Lemoli RM. Extracellular ATP exerts opposite effects on activated
and regulatory CD4+ T cells via purinergic P2 receptor activation. J Immunol. 2012 Aug
1;189(3):1303-10. (5,5)
6. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V,
Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M,
Velardi A, Lemoli RM. Successful transfer of alloreactive haploidentical KIR ligand-
mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia
patients. Blood. 2011 Sep 22;118(12):3273-9. (9,06)
7. Sollazzo D, Trabanelli S, Curti A, Vianelli N, Lemoli RM, Catani L. Circulating
CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia.
Haematologica. 2011 Apr;96(4):632-4. (5,9)
8. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V,
Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM. The addition of
plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma
patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant. 2011
Mar;46(3):356-63. (3,5)
9. Trabanelli S, Ocadlikova D, Evangelisti C, Parisi S, Curti A. Induction of regulatory T
Cells by dendritic cells through indoleamine 2,3-dioxygenase: a potent mechanism of
acquired peripheral tolerance. Curr Med Chem. 2011;18(15):2234-9. (4,07)
10. Curti A, Trabanelli S, Onofri C, Aluigi M, Salvestrini V, Ocadlikova D, Evangelisti C,
Rutella S, De Cristofaro R, Ottaviani E, Baccarani M, Lemoli RM. Indoleamine 2,3dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune
response by inducing potent T regulatory cells. Haematologica. 2010 Dec;95(12):2022-30.
(5,9)
11. Papayannidis C, Iacobucci I, Abbenante MC, Curti A, Parisi S, Paolini S, Testoni N,
Baccarani M, Cilloni D, Martinelli G. Philadelphia positive (Ph+) acute lymphoblastic
leukemia (ALL) patient with breast infiltration. Leuk Res. 2010 Sep;34(9):e246-7. (2,5)
12. Papayannidis C, Iacobucci I, Abbenante MC, Curti A, Paolini S, Parisi S, Baccarani M,
Martinelli G. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic
leukemia adult patient. Am J Hematol. 2010 Aug;85(8):608. (4,1)
13. Papayannidis C, Derenzini E, Iacobucci I, Curti A, Paolini S, Cilloni D, Baccarani M,
Martinelli G. Successful combination treatment of clofarabine, cytarabine, and
gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia. Am J
Hematol. 2009 Dec;84(12):849-50. (4,1)
14. Curti A, Trabanelli S, Salvestrini V, Baccarani M, Lemoli RM. The role of indoleamine
2,3-dioxygenase in the induction of immune tolerance: focus on hematology. Blood. 2009
Mar 12;113(11):2394-401. (9,06)
15. Curti A, Trabanelli S, Lemoli RM. More ADO about IDO: GVHD. Blood. 2008 Mar
15;111(6):2950. (9,06)
16. Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C, Massaia M, D'Addio A, Giudice
V, Di Bello C, Cavo M, Conte R, Gugliotta G, Baccarani M, Lemoli RM. Phase I/II clinical
trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for
refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype
(VDJ)-derived class I-restricted peptides. Br J Haematol. 2007 Nov;139(3):415-24. (4,9)
17. Isidori A, Motta MR, Tani M, Terragna C, Zinzani P, Curti A, Rizzi S, Taioli S, Giudice V,
D'Addio A, Gugliotta G, Conte R, Baccarani M, Lemoli RM. Positive selection and
transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed
chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without
an adequate leukemic cell purging. Biol Blood Marrow Transplant. 2007 Oct;13(10):122432. (3,9)
18. Curti A, Pandolfi S, Valzasina B, Aluigi M, Isidori A, Ferri E, Salvestrini V, Bonanno G,
Rutella S, Durelli I, Horenstein AL, Fiore F, Massaia M, Colombo MP, Baccarani M,
Lemoli RM. Modulation of tryptophan catabolism by human leukemic cells results in the
conversion of CD25- into CD25+ T regulatory cells. Blood. 2007 Apr 1;109(7):2871-7.
(9,06)
19. Curti A, Aluigi M, Pandolfi S, Ferri E, Isidori A, Salvestrini V, Durelli I, Horenstein AL,
Fiore F, Massaia M, Piccioli M, Pileri SA, Zavatto E, D'Addio A, Baccarani M, Lemoli RM.
Acute myeloid leukemia cells constitutively express the immunoregulatory enzyme
indoleamine 2,3-dioxygenase. Leukemia. 2007 Feb;21(2):353-5. (10,1)
20. Rutella S, Bonanno G, Procoli A, Mariotti A, de Ritis DG, Curti A, Danese S, Pessina G,
Pandolfi S, Natoni F, Di Febo A, Scambia G, Manfredini R, Salati S, Ferrari S, Pierelli L,
Leone G, Lemoli RM. Hepatocyte growth factor favors monocyte differentiation into
regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features.
Blood. 2006 Jul 1;108(1):218-27. (9,06)
21. Catani L, Fagioli ME, Tazzari PL, Ricci F, Curti A, Rovito M, Preda P, Chirumbolo G,
Amabile M, Lemoli RM, Tura S, Conte R, Baccarani M, Vianelli N. Dendritic cells of
immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic
platelets to T lymphocytes. Exp Hematol. 2006 Jul;34(7):879-87. (2,9)
22. Ferrari D, Pizzirani C, Adinolfi E, Lemoli RM, Curti A, Idzko M, Panther E, Di Virgilio F.
The P2X7 receptor: a key player in IL-1 processing and release. J Immunol. 2006 Apr
1;176(7):3877-83. (5,5)
23. Aluigi M, Fogli M, Curti A, Isidori A, Gruppioni E, Chiodoni C, Colombo MP, Versura P,
D'Errico-Grigioni A, Ferri E, Baccarani M, Lemoli RM. Nucleofection is an efficient
nonviral transfection technique for human bone marrow-derived mesenchymal stem cells.
Stem Cells. 2006 Feb;24(2):454-61. (7,7)
24. Scotlandi K, Perdichizzi S, Bernard G, Nicoletti G, Nanni P, Lollini PL, Curti A, Manara
MC, Benini S, Bernard A, Picci P. Targeting CD99 in association with doxorubicin: an
effective combined treatment for Ewing's sarcoma. Eur J Cancer. 2006 Jan;42(1):91-6. (5,2)
25. Curti A, Pandolfi S, Aluigi M, Isidori A, Alessandrini I, Chiodoni C, Testoni N, Colombo
MP, Baccarani M, Lemoli RM. Interleukin-12 production by leukemia-derived dendritic
cells counteracts the inhibitory effect of leukemic microenvironment on T cells. Exp
Hematol. 2005 Dec;33(12):1521-30. (2,9)
26. Isidori A, Tani M, Bonifazi F, Zinzani P, Curti A, Motta MR, Rizzi S, Giudice V, Farese O,
Rovito M, Alinari L, Conte R, Baccarani M, Lemoli RM. Phase II study of a single
pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the
peripheral blood of pretreated lymphoma patients. Haematologica. 2005 Feb;90(2):225-31.
(5,9)
27. Curti A, Isidori A, Ferri E, Terragna C, Neyroz P, Cellini C, Ratta M, Baccarani M, Lemoli
RM. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor
immunotherapy. Leuk Lymphoma. 2004 Jul;45(7):1419-28. (2,3)
28. Rutella S, Bonanno G, Pierelli L, Mariotti A, Capoluongo E, Contemi AM, Ameglio F,
Curti A, De Ritis DG, Voso MT, Perillo A, Mancuso S, Scambia G, Lemoli RM, Leone G.
Granulocyte colony-stimulating factor promotes the generation of regulatory DC through
induction of IL-10 and IFN-alpha. Eur J Immunol. 2004 May;34(5):1291-302. (4,9)
29. Curti A, Ferri E, Pandolfi S, Isidori A, Lemoli RM. Dendritic cell differentiation. J
Immunol. 2004 Jan 1;172(1):3. (5,5)
30. Lemoli RM, Bertolini F, Petrucci MT, Gregorj C, Ricciardi MR, Fogli M, Curti A,
Rabascio C, Pandolfi S, Ferrari S, Foá R, Baccarani M, Tafuri A. Functional and kinetic
characterization of granulocyte colony-stimulating factor-primed CD34- human stem cells.
Br J Haematol. 2003 Nov;123(4):720-9. (4,9)
31. Lemoli RM, de Vivo A, Damiani D, Isidori A, Tani M, Bonini A, Cellini C, Curti A,
Gugliotta L, Visani G, Fanin R, Baccarani M. Autologous transplantation of granulocyte
colony-stimulating factor-primed bone marrow is effective in supporting myeloablative
chemotherapy in patients with hematologic malignancies and poor peripheral blood stem
cell mobilization. Blood. 2003 Sep 1;102(5):1595-600. (9,06)
32. Motta MR, Castellani S, Rizzi S, Curti A, Gubinelli F, Fogli M, Ferri E, Cellini C,
Baccarani M, Lemoli RM. Generation of dendritic cells from CD14+ monocytes positively
selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical
trial of anti-idiotype vaccination. Br J Haematol. 2003 Apr;121(2):240-50. (4,9)
33. Curti A, Parenza M, Colombo MP. Autologous and MHC class I-negative allogeneic tumor
cells secreting IL-12 together cure disseminated A20 lymphoma. Blood. 2003 Jan
15;101(2):568-75. (9,06)
34. Lemoli RM, Curti A, Fogli M, Ferri E, Baccarani M. The therapeutic role of dendritic cells
in cancer immunotherapy. Haematologica. 2002 Aug;87(8 Suppl):62-6. (5,9)
35. Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della
Cuna GR, Tura S, Baccarani M, Lemoli RM. Dendritic cells are functionally defective in
multiple myeloma: the role of interleukin-6. Blood. 2002 Jul 1;100(1):230-7. (9,06)
36. Curti A, Colombo MP, Baccarani M, Lemoli RM. Transduction of MHC-class I negative
allogeneic cell line to improve the efficacy of anti-tumor vaccination. J Biol Regul Homeost
Agents. 2002 Jul-Sep;16(3):236-40.
37. Curti A, Tafuri A, Ricciardi MR, Tazzari P, Petrucci MT, Fogli M, Ratta M, Lapalombella
R, Ferri E, Tura S, Baccarani M, Lemoli RM. Interleukin-11 induces proliferation of human
T-cells and its activity is associated with downregulation of p27(kip1). Haematologica. 2002
Apr;87(4):373-80. (5,9)
38. Tazzari PL, Polito L, Bolognesi A, Pistillo MP, Capanni P, Palmisano GL, Lemoli RM,
Curti A, Biancone L, Camussi G, Conte R, Ferrara GB, Stirpe F. Immunotoxins containing
recombinant anti-CTLA-4 single-chain fragment variable antibodies and saporin: in vitro
results and in vivo effects in an acute rejection model. J Immunol. 2001 Oct 15;167(8):42229. (5,5)
39. Curti A, Ratta M, Corinti S, Girolomoni G, Ricci F, Tazzari P, Siena M, Grande A, Fogli
M, Tura S, Lemoli RM. Interleukin-11 induces Th2 polarization of human CD4(+) T cells.
Blood. 2001 May 1;97(9):2758-63. (9,06)
40. Curti A, Fogli M, Ratta M, Tura S, Lemoli RM. Stem cell factor and FLT3-ligand are
strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell
precursors. J Immunol. 2001 Jan 15;166(2):848-54. (5,5)
41. Curti A, Fogli M, Ratta M, Biasco G, Tura S, Lemoli RM. Dendritic cell differentiation
from hematopoietic CD34+ progenitor cells. J Biol Regul Homeost Agents. 2001 JanMar;15(1):49-52.
42. Ratta M, Curti A, Fogli M, Pantucci M, Viscomi G, Tazzari P, Fagnoni F, Vescovini R,
Sansoni P, Tura S, Lemoli RM. Efficient presentation of tumor idiotype to autologous T
cells by CD83(+) dendritic cells derived from highly purified circulating CD14(+)
monocytes in multiple myeloma patients. Exp Hematol. 2000 Aug;28(8):931-40. (2,9)
43. Fogli M, Carlo-Stella C, Curti A, Ratta M, Tazzari PL, Ragazzi E, Colla S, Santucci AM,
Tura S, Lemoli RM. Transforming growth factor beta3 inhibits chronic myelogenous
leukemia hematopoiesis by inducing Fas-independent apoptosis. Exp Hematol. 2000
Jul;28(7):775-83. (2,9)
44. Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S, Terragna C, Rondelli R, Ronconi
S, Curti A, Bonifazi F, Tura S, Cavo M. Engraftment, clinical, and molecular follow-up of
patients with multiple myeloma who were reinfused with highly purified CD34+ cells to
support single or tandem high-dose chemotherapy. Blood. 2000 Apr 1;95(7):2234-9. (9,06)
45. Rondelli D, Lemoli RM, Ratta M, Fogli M, Re F, Curti A, Arpinati M, Tura S. Rapid
induction of CD40 on a subset of granulocyte colony-stimulating factor-mobilized CD34(+)
blood cells identifies myeloid committed progenitors and permits selection of
nonimmunogenic CD40(-) progenitor cells. Blood. 1999 Oct 1;94(7):2293-300. (9,06)
46. Lemoli RM, Curti A, Tura S. Negative selection of autologous peripheral blood stem cells.
Baillieres Best Pract Res Clin Haematol. 1999 Mar-Jun;12(1-2):57-69. (5,1)
47. Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk
leukemia patients: a pilot study. Bone Marrow Transplant. 1999 Feb;23(3):235-41. (3,5)
48. Ratta M, Rondelli D, Fortuna A, Curti A, Fogli M, Fagnoni F, Martinelli G, Terragna C,
Tura S, Lemoli RM. Generation and functional characterization of human dendritic cells
derived from CD34 cells mobilized into peripheral blood: comparison with bone marrow
CD34+ cells. Br J Haematol. 1998 Jun;101(4):756-65. (4,9)
49. Fogli M, Amabile M, Martinelli G, Fortuna A, Rondelli D, Ratta M, Curti A, Tura S,
Lemoli RM. Selective expansion of normal haemopoietic progenitors from chronic
myelogenous leukaemia marrow. Br J Haematol. 1998 Apr;101(1):119-29. (4,9)
50. Lemoli RM, Bandini G, Leopardi G, Rosti G, Bonini A, Fortuna A, Rondelli D, Mangianti
S, Motta MR, Rizzi S, Tassi C, Cavo M, Remiddi C, Curti A, Conte R, Tura S. Allogeneic
peripheral blood stem cell transplantation in patients with early-phase hematologic
malignancy: a retrospective comparison of short-term outcome with bone marrow
transplantation. Haematologica. 1998 Jan;83(1):48-55. (5,9)
I hereby certify that this document is an accurate representation of my qualifications.
Date of signature
17/07/2014
Signature
According to the Italian law 196/2003 I authorize the release of my personal data.